Open access · CC-BY
via OpenAlex
Pharmacotherapeutics and molecular docking studies of alpha-synuclein modulators as promising therapeutics for Parkinson’s disease
RAHAT ALI, Aftab Alam, Satyendra Kumar Rajput, RAZI AHMAD
Biocell · 2022 · ▲ 10 citations
Abstract
Parkinson’s disease (PD) is an age-related neurodegenerative ailment that affects dopamine-producing neurons in a specific area of the brain called the substantia nigra of the ventral midbrain. It is clinically characterized by movement disorder and marked with unusual synaptic protein alpha-synuclein accumulation in the brain. To date, only a few Food and Drug Administration (FDA) approved drugs are available on the market for the treatment of PD. Nonetheless, these drugs show parasympathomimetic related adverse events and remarkably higher toxicity; hence, it is important to find more efficacious molecules to treat PD. In our study, We chosen 22 natural compounds as inhibitors that potentially block the alpha-synuclein clump—the pathological hallmark of PD—and provide new avenues for its treatment. Most of these molecules exhibited good pharmacokinetic behaviors, making them decisively favorable drug candidates to cure PD. Molecular docking studies were performed to investigate the binding interactions between natural compounds and alpha-synuclein as anti-Parkinson drug targets. Among the examined compounds, curcumin and piperine emerged as promising phytochemicals with the highest binding affinity, key residual stable bindings and showed a good inhibitory features. Thus, the present study indicates that curcumin and piperine hold the potential to be developed as treatment options against PD. Experimental validations are needed for insights into their mechanism of action and potential clinical application.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.32604/biocell.2022.021224
- Canonical
- link ↗
- Fetched
- 2026-10-27 MST
Cite this
APA
ALI, R., Alam, A., Rajput, S.K., & AHMAD, R. (2022). Pharmacotherapeutics and molecular docking studies of alpha-synuclein modulators as promising therapeutics for Parkinson’s disease. <em>Biocell</em>. https://doi.org/10.32604/biocell.2022.021224
Vancouver
ALI R, Alam A, Rajput SK, AHMAD R. Pharmacotherapeutics and molecular docking studies of alpha-synuclein modulators as promising therapeutics for Parkinson’s disease. Biocell. 2022. doi:10.32604/biocell.2022.021224.
BibTeX
@article{rahat2022Pharma,
title = {Pharmacotherapeutics and molecular docking studies of alpha-synuclein modulators as promising therapeutics for Parkinson’s disease},
author = {RAHAT ALI and Aftab Alam and Satyendra Kumar Rajput and RAZI AHMAD},
journal = {Biocell},
year = {2022},
doi = {10.32604/biocell.2022.021224},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Scientific Reports 2019
Open access · CC-BY
A Frailty Index based on clinical data to quantify mortality risk in dogs
UNC Lineberger Comprehensive Cancer Center 2011
Open access · US-GOV
A Phase II Trial Of Ofatumumab In Older (≥70 Years) Patients With Previously Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
Skeletal Muscle 2026
Open access · CC-BY
Caloric restriction reprograms skeletal muscle molecular pathways in non-human primates: potential relevance to human aging biology
Skeletal muscle 2026
Open access · OA
Caloric restriction reprograms skeletal muscle molecular pathways in non-human primates: potential relevance to human aging biology.
Figshare 2026
Preprint · CC-BY
Caloric restriction reprograms skeletal muscle molecular pathways in non-human primates: potential relevance to human aging biology
Bioinformatics 2018
Preprint · OA